摘要
目的动态的监测bcr-abl融合基因mRNA表达水平以及评估经格列卫治疗后的慢性粒细胞白血病(CML)患者微小残留病灶。方法荧光定量RT-PCR法(Q-RT-PCR)检测bcr-abl融合基因mRNA表达水平,收集来自广州金域的34例CML患者(包括经格列卫治疗后缓解病人17例,未经治疗病人17例)。CML患者的检测结果与其他良性血液病患者进行比较,并且结合临床表现,得到CML和其它非白血病病人中bcr-abl L表达信息,以及在慢性粒细胞白血病的治疗中微小残留病灶的重要意义。结果在CML病人中bcr-abl融合基因表达阳性率为88.3%(30/34),在其他的良性血液病中无表达。我们也能观察到经格列卫治疗的病人有一定的治疗效果,经格列卫治疗的病人bcr-abl融合基因的表达水平较未经治疗者明显降低(P<0.05)。结论 Q-RT-PCR法是检测慢性粒细胞白血病微小残留病灶的重要方法,BCR-ABL融合基因可以做为CML的分子标志。
Objective To detect the expression level of mRNA of bcr-abl fusion gene dynamical ly, and evaluate minimal residual disease (MRD) after therapy by Glivec (Imatinib Mesylate Capsules) for the patients of chronic myelocytic leukemia (CML). Methods Expression levels of bcr-abl fusion gene mRNA was detected by Real Time Quantitative PCR (RQ-PCR) technique. 34 samples from CML patients (including 17 patients treated with Glivec and 17 untreated patients) were collected from Kingmed. The expression levels of bcr-abl fusion gene mRNA CML patients were compared with that of the patients with other benign blood tumors, and combined with clinical situation, to explore the correlation of expression of bcr-abl between CML patients and others, and the significance of minimal residual disease (MRD) on CML's therapy. Results Expression of bcr-abl was 88.3% (30/34) in CML, and no expression in the patients with benign blood disease was found. The patients treated with Glivec who showed improvement was observed, too. The expression of bcr-abl is lower than those untreated patients (P〈0.05). Conclusion RQ-PCR was the suitable method for monitored MRD in CML, bcr-abl could serve as a molecular mark for CML.
出处
《分子诊断与治疗杂志》
2014年第4期239-244,共6页
Journal of Molecular Diagnostics and Therapy
基金
广东省医学科研基金(A2012603)